{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:28:41Z","timestamp":1786796921197,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111705","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:51:08Z","timestamp":1784533868000},"page":"111705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Putting PROTEUS into perspective: treatment intensification in high-risk localized prostate cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"V\u00e9rane","family":"Achard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-5839","authenticated-orcid":false,"given":"Alfonso","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-4848","authenticated-orcid":false,"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111705_b0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603878","article-title":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","author":"Taplin","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111705_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109544","article-title":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","volume":"183","author":"Schmidt-Hegemann","year":"2023","journal-title":"Radiother Oncol"},{"issue":"10323","key":"10.1016\/j.radonc.2026.111705_b0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.radonc.2026.111705_b0020","doi-asserted-by":"crossref","first-page":"S1628","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.radonc.2026.111705_b0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2025.06.009","article-title":"Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer","volume":"9","author":"Roy","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"5\u20136","key":"10.1016\/j.radonc.2026.111705_b0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/21681805.2018.1520295","article-title":"SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer","volume":"52","author":"Stranne","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.radonc.2026.111705_b0035","doi-asserted-by":"crossref","unstructured":"Morgans, A.K., et al., Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. NEJM Evid, 2025. 4(11): p. EVIDoa2500109.","DOI":"10.1056\/EVIDoa2500109"},{"key":"10.1016\/j.radonc.2026.111705_b0040","doi-asserted-by":"crossref","unstructured":"Fizazi, K., et al., Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial. Journal of Clinical Oncology, 2026. 44(7_suppl): p. LBA307-LBA307.","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA307"},{"key":"10.1016\/j.radonc.2026.111705_b0045","article-title":"Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer","author":"Spratt","year":"2023","journal-title":"Res Sq"},{"key":"10.1016\/j.radonc.2026.111705_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.05.708","article-title":"Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer","author":"Parker","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2026.111705_b0055","first-page":"1024","article-title":"The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making. Eur Urol","volume":"9","author":"Venderbos","year":"2023","journal-title":"Focus"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600544X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600544X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:19:32Z","timestamp":1786796372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402600544X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":11,"alternative-id":["S016781402600544X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111705","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Putting PROTEUS into perspective: treatment intensification in high-risk localized prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111705"}}